Morphological Features of Minimal Change Disease and Focal Segmental Glomerulosclerosis Using Repeat Biopsy and Parietal Epithelial Cell Marker

Overview

Journal Kidney Dis (Basel)

Specialty Nephrology

Date 2020 Apr 21

PMID 32309294

Citations 5

Authors

Tomo Suzuki

Kaori Kohatsu

Wei Han

Shiika Watanabe

Koichi Yahagi

Mayumi Nakata

Toshiharu Ueno

Daisuke Ichikawa

Naohiko Imai

Sayuri Shirai

Junki Koike

Yugo Shibagaki

Affiliations

Soon will be listed here.

Abstract

Introduction: Minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) are representative podocyte diseases. The clinical cause of MCD and FSGS has not been clearly elucidated yet. However, it is important to distinguish MCD and FSGS because their prognoses and responses to treatment are quite different.

Objective: This study aimed to examine whether parietal epithelial cell (PEC) marker and repeat biopsy are useful for diagnosing primary FSGS.

Methods: Clinicopathological features of 17 patients with the nephrotic syndrome, who underwent kidney biopsy ≥2 times from 1975 to 2017, and had MCD or FSGS were analyzed using PAX8. We defined patients with PAX8+ cells as PAX8+ and the remainder as PAX8- patients. Three cases of sample insufficiency and 1 non-steroid-resistant or frequently relapsing case indicated for repeat biopsy were excluded.

Results: Among the 13 patients studied, 4 were PAX8+ and 9 were PAX8- (median age: 41 and 46 years, -respectively, at first biopsy). PAX8+ and PAX8- patients showed no significant differences in clinical data and histological diagnosis except for a significant difference in histological diagnosis at the second biopsy. The number of PAX8+ patients increased to 6. Unlike the first biopsy results, FSGS was present in 5 of 6 (83.3%) PAX8+ patients; MCD occurred in all 7 (100%) PAX8- patients. Three of 6 (50.0%) PAX8+ patients undergoing repeat biopsy were steroid resistant; no (0%) PAX8- patient was steroid resistant. All cases of final FSGS diagnosis were PAX8+ at the first or second biopsy. Only 1 PAX8+ MCD patient was steroid resistant. All PAX8- MCD patients were frequently relapsing.

Conclusions: More PAX8+ patients were diagnosed with FSGS than PAX8- patients. Clinical presentation of MCD in PAX8- patients was frequently relapsing. PEC marker staining in patients with the nephrotic syndrome, e.g., MCD, may help to diagnose FSGS.

Citing Articles

Identification of Genes Associated with Familial Focal Segmental Glomerulosclerosis Through Transcriptomics and In Silico Analysis, Including , , and .

Mahmoud A, Alhamidi R, Ilce B, Hamad A, Ali N, Mahasneh A Int J Mol Sci. 2024; 25(21).

PMID: 39519211 PMC: 11546068. DOI: 10.3390/ijms252111659.

Transition from minimal change disease to focal segmental glomerulosclerosis related to occupational exposure: A case report.

Tang L, Cai Z, Wang S, Zhao W World J Clin Cases. 2022; 10(17):5861-5868.

PMID: 35979127 PMC: 9258360. DOI: 10.12998/wjcc.v10.i17.5861.

The Role of Parietal Epithelial Cells in the Pathogenesis of Podocytopathy.

Li Z, Guo X, Quan X, Yang C, Liu Z, Su H Front Physiol. 2022; 13:832772.

PMID: 35360248 PMC: 8963495. DOI: 10.3389/fphys.2022.832772.

Biopsy or Biomarker? Children With Minimal Change Disease Have a Distinct Profile of Urinary Epidermal Growth Factor.

Lodeweyckx N, Wouters K, Ledeganck K, Trouet D Front Pediatr. 2021; 9:727954.

PMID: 34900856 PMC: 8657767. DOI: 10.3389/fped.2021.727954.

Extracellular vesicles mediate cellular interactions in renal diseases-Novel views of intercellular communications in the kidney.

Zhang P, Liu M J Cell Physiol. 2021; 236(8):5482-5494.

PMID: 33432614 PMC: 9107954. DOI: 10.1002/jcp.30268.

References

Nishi S, Ubara Y, Utsunomiya Y, Okada K, Obata Y, Kai H . Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol. 2016; 20(3):342-70. PMC: 4891386. DOI: 10.1007/s10157-015-1216-x. View

Uezono S, Hara S, Sato Y, Komatsu H, Ikeda N, Shimao Y . Renal biopsy in elderly patients: a clinicopathological analysis. Ren Fail. 2006; 28(7):549-55. DOI: 10.1080/08860220600840165. View

DAgati V, Kaskel F, Falk R . Focal segmental glomerulosclerosis. N Engl J Med. 2011; 365(25):2398-411. DOI: 10.1056/NEJMra1106556. View

Ahmad H, Tejani A . Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron. 2000; 84(4):342-6. DOI: 10.1159/000045609. View

Korbet S, Volpini K, Whittier W . Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies. Am J Nephrol. 2014; 39(2):153-62. DOI: 10.1159/000358334. View

Hogan J, Bomback A, Mehta K, Canetta P, Rao M, Appel G . Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin J Am Soc Nephrol. 2013; 8(12):2072-81. PMC: 3848392. DOI: 10.2215/CJN.02840313. View

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K . Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014; 384(9950):1273-81. DOI: 10.1016/S0140-6736(14)60541-9. View

WEBB N, Lewis M, Iqbal J, Smart P, Lendon M, Postlethwaite R . Childhood steroid-sensitive nephrotic syndrome: does the histology matter?. Am J Kidney Dis. 1996; 27(4):484-8. DOI: 10.1016/s0272-6386(96)90157-2. View

Wada T, Pippin J, Marshall C, Griffin S, Shankland S . Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J Am Soc Nephrol. 2005; 16(9):2615-25. DOI: 10.1681/ASN.2005020142. View

10.

Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat C, Busch M . Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol. 2014; 39(4):322-30. DOI: 10.1159/000360908. View

11.

Rich A . A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipoid nephrosis. Bull Johns Hopkins Hosp. 1957; 100(4):173-86. View

12.

Katsuno T, Masuda T, Saito S, Kato N, Ishimoto T, Kato S . Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study. Clin Exp Nephrol. 2018; 23(2):207-214. DOI: 10.1007/s10157-018-1630-y. View

13.

Sakamoto K, Ueno T, Kobayashi N, Hara S, Takashima Y, Pastan I . The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis. Am J Physiol Renal Physiol. 2013; 306(1):F98-F104. PMC: 3921819. DOI: 10.1152/ajprenal.00228.2013. View

14.

Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A . Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med. 2012; 366(17):1648-9. DOI: 10.1056/NEJMc1202500. View

15.

Fatima H, Moeller M, Smeets B, Yang H, DAgati V, Alpers C . Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol. 2012; 7(11):1852-8. PMC: 3488951. DOI: 10.2215/CJN.10571011. View

16.

Smeets B, Stucker F, Wetzels J, Brocheriou I, Ronco P, Grone H . Detection of activated parietal epithelial cells on the glomerular tuft distinguishes early focal segmental glomerulosclerosis from minimal change disease. Am J Pathol. 2014; 184(12):3239-48. PMC: 5707202. DOI: 10.1016/j.ajpath.2014.08.007. View

17.

Ueno T, Kobayashi N, Nakayama M, Takashima Y, Ohse T, Pastan I . Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int. 2013; 83(6):1065-75. PMC: 7567340. DOI: 10.1038/ki.2013.48. View

18.

Canaud G, Dion D, Zuber J, Gubler M, Sberro R, Thervet E . Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant. 2009; 25(4):1321-8. DOI: 10.1093/ndt/gfp500. View

19.

Maas R, Deegens J, Smeets B, Moeller M, Wetzels J . Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016; 12(12):768-776. DOI: 10.1038/nrneph.2016.147. View

20.

Stadermann M, Lilien M, van de Kar N, Monnens L, Schroder C . Is biopsy required prior to cyclophosphamide in steroid-sensitive nephrotic syndrome?. Clin Nephrol. 2003; 60(5):315-7. DOI: 10.5414/cnp60315. View